Despite alternative binding modalities, S55746 binds to G101V mutant BCL2 with 100-fold lower affinity compared to wildtype BCL2.320 Two clinical trials were completed; firstly, to assess the safety and tolerability of S55746 in CLL and NHL (NCT02920697), and secondly, to assess the combination of S55746 and the PI3K inhibitor, idelalisib, in FL and MCL (NCT02603445). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.